Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

Background: Carcinoma of unknown primary (CUP) accounts for 3-5% of all adult solid tumors. An extensive search for the anatomic site of origin is often undertaken in an attempt to tailor systemic treatment, but the latter often has limited efficacy - especially in the setting of an initial treatmen...

Full description

Bibliographic Details
Main Authors: Norma A. Palma, Siraj M. Ali, Jamie O'Connor, Deepa Dutta, Kai Wang, Salil Soman, Gary A. Palmer, Deborah Morosini, Jeffrey S. Ross, Doron Lipson, Phil J. Stephens, Mayur Patel, Vincent A. Miller, Nicholas Koutrelakos
Format: Article
Language:English
Published: Karger Publishers 2014-07-01
Series:Case Reports in Oncology
Subjects:
MET amplification
KRAS mutation
Crizotinib
Next-generation sequencing
Carcinoma of unknown primary
Online Access:http://www.karger.com/Article/FullText/365326

Internet

http://www.karger.com/Article/FullText/365326

Similar Items